Author(s): LEI Yuan-yuan, WU Si-pei, DONG Zhong-yi, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute
Pages: 132-133
Year: 2016 Issue:  3
Journal: Journal of Evidence-Based Medicine
Keyword:  small cell lung cancer; immunotherapy;
Abstract: <正>小细胞肺癌(small cell lung cancer,SCLC)是一类侵袭性很强的肿瘤,因为肿瘤基因突变谱异常复杂,一直没有发现有意义的治疗靶点,几十年来,SCLC的治疗仍然停留在放化疗为主的传统时代。SCLC的二线治疗更是举步维艰,目前唯一获批的二线治疗药物是Topotecan,但疗效非常有限,既往报道二线Topotecan单药有效率仅为7%,无进